Ajanta Pharmaceuticals
BSE: 532331 | NSE: AJANTPHARM | ISIN: INE031B01049 | SECTOR: Biotechnology & DrugsOpen
1,920.85High
1,965.15Low
1,906.60Prev Close
1,920.85P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
245.33BVolume
3.57KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
1,948.40Ask
-
Promoter Pledge Holding - 8.23%
Promoter Name | No of Shares | Percentage |
---|---|---|
Ravi P Agrawal, trustee Ravi Agrawal Trust | 55,78,929 | 4.42% |
Aayush M Agrawal, trustee Aayush Agrawal Trust | 47,88,207 | 3.80% |
Company Description
- Biotechnology & Drugs
BSE
532331NSE
AJANTPHARMISIN
INE031B01049
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
Company Officers
Madhusudan Agrawal
Executive Vice Chairman of the BoardArvind Agrawal
Chief Financial OfficerGaurang Shah
Vice President - Legal, Company SecretaryRajesh Agrawal
Joint Managing Director, Executive DirectorYogesh Agrawal
Managing Director, Executive Director